Results 151 to 160 of about 1,973 (178)
Some of the next articles are maybe not open access.
Multifaceted skeletal effects of sevelamer carbonate in a secondary hyperparathyroidism model
EndocrineHyperphosphatemia leads to abnormal mineralization of bones and soft tissues in patients with chronic kidney disease-induced secondary hyperparathyroidism (CKD-SHPT). Sevelamer lowers phosphate levels by binding to dietary phosphate in the gastrointestinal system, forming new bone and reducing the risk of renal osteodystrophy and fracture. However, the
Shivani, Sharma +12 more
openaire +2 more sources
Relative in Vitro Efficacy of the Phosphate Binders Lanthanum Carbonate and Sevelamer Hydrochloride
Journal of Pharmaceutical Sciences, 2007The high tablet burden and poor compliance associated with phosphate-binding drugs has led to a search for more potent agents. In vitro-binding studies were performed on the recently introduced binder, lanthanum carbonate (LC; Fosrenol), to compare its phosphate-binding affinity with sevelamer hydrochloride (SH; Renagel).
Autissier V, Damment SJP, Henderson RA
openaire +3 more sources
Formulation and characterization of sevelamer carbonate immediate release tablets
International Journal of Experimental and Biomedical ResearchThe present study aimed to formulate and evaluate a pharmaceutical study on formulating and characterising immediate - release tablets of Sevelamer carbonate, a non - absorbable phosphate binder used to treat hyperphosphatemia in chronic kidney disease patient s.Six formulations (F1 - F6) were developed using wet granulation with varying super ...
{\\"name\\":\\"Vadamala Prudhvi Raj\\",\\"email\\":\\"prudhvirajpharma9@gmail.com\\",\\"affiliat +7 more
openaire +1 more source
Efficacy of Sevelamer Hydrochloride and Sevelamer Carbonate in Hyperphosphatemia Condition-A Review
Asian Journal of Research in Chemistry, 2018Priya C. Mouli +3 more
openaire +1 more source